首次治疗后177Lu-PSMA SPECT/CT评估基线PSMA PET/CT至治疗间期内的 interim 进展
该研究在87例雄激素通路受体调节剂抵抗性前列腺癌患者中,用首次177Lu-PSMA-617治疗后SPECT/CT评估 interim 疾病进展。32例(36.8%)出现 interim 进展,其基线PSMA PET至治疗启动间期(88天)显著长于无进展者(42天,P<0.001)。基线PET至治疗超过30天者中约94%出现 interim 进展,但 interim 进展未影响PSA反应和总生存。
要点
- 36.8%患者首次治疗后SPECT/CT可见 interim 疾病进展。
- interim 进展者基线PET至治疗间期88天,显著长于无进展者42天。
- 基线PET至治疗超过30天者约94%出现 interim 进展。
核心结论
- 若首次177Lu-PSMA-617治疗在基线PSMA PET后超过30天进行,基线PET可能不能代表真实疾病状态。
研究设计与样本
- 研究对87例雄激素通路受体调节剂抵抗性前列腺癌患者进行视觉评估,比较有无 interim 进展者的PET至治疗间期、治疗前PSA及治疗结局。
主要发现
- 32例(36.8%)在首次治疗后177Lu-PSMA-617 SPECT/CT上出现 interim 进展。
- interim 进展者PET至治疗间期为88天,显著长于无进展者的42天(P<0.001),校正年龄、Gleason分级和PSA倍增时间后仍显著。
- 基线PSMA PET至治疗启动间期超过30天者中约94%出现 interim 进展。
- interim 进展未影响PSA反应和总生存。
关键数值与推荐
- 基线PSMA PET至首次177Lu-PSMA-617治疗间期超过30天与 interim 进展高发相关。
临床怎么用
- 对计划177Lu-PSMA-617治疗的患者,应关注基线PSMA PET与首次治疗的时间间隔,超过30天时需警惕 interim 进展可能影响基线PET的疗效评估代表性。
以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。
原文
Prostate Cancer Working Group 4 recommends using prostate-specific membrane antigen (PSMA) PET for response assessment of patients with androgen pathway receptor modulator-resistant prostate cancer treated with 177Lu-PSMA-617. For that purpose, the time interval between baseline PSMA PET and initiation of therapy is critical as interim disease progression may influence the performance of PET as a response assessment tool. Methods: We visually assessed the frequency of interim disease progression seen on the first posttherapy 177Lu-PSMA-617 SPECT/CT in 87 patients with androgen pathway receptor modulator-resistant prostate cancer. The time interval between baseline PSMA PET and initiation of therapy, pretherapy prostate-specific antigen (PSA) measures, and treatment outcomes between patients with or without interim progression on SPECT/CT were also compared. Results: For the 32 patients (36.8%) with interim progression, the PET to therapy interval (88 d) was significantly greater than those without progression (42 d, P < 0.001) despite adjusting for age, Gleason grade, and PSA doubling time. A time interval between baseline PSMA PET and initiation of therapy exceeding 30 d was seen in approximately 94% of patients with interim progression. PSA response and overall survival were not impacted by interim progression. Conclusion: Baseline PSMA PET may not represent the true disease status if the first cycle of 177Lu-PSMA-617 occurs more than 30 d after baseline PET.
引用
- Parihar AS, Dehdashti F, Pant N, et al. Evaluating Interim Progression: First Posttherapy 177Lu-PSMA SPECT/CT Relative to Baseline PSMA PET/CT. J Nucl Med. 2026. PMID: 42492999. doi:10.2967/jnumed.126.272545
供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。